Clinical Trial Update: A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) [Phase 3]

View source ↗

Summary

A Phase 3 pilot study at the University of Zurich is evaluating teriparatide (Forsteo) for improving bone mineral density and bone fragility in anorexia nervosa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anorexia Nervosa
• Osteoporosis

Drugs mentioned

• Forsteo® (teriparatide)

Snippet

Sponsor: University of Zurich | Conditions: Low Bone Mass in Anorexia Nervosa Patients | Phase 3 | Status: UNKNOWN